XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 27, 2024
Jun. 30, 2025
Oct. 31, 2023
Sep. 30, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2026
Dec. 31, 2024
Oct. 14, 2025
Jun. 27, 2025
Mar. 20, 2025
Nov. 30, 2024
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue         $ 1,164,617 $ 1,957,500   $ 2,524,819 $ 2,678,013              
Restricted cash and cash equivalents $ 1,321,278       1,321,278   1,321,278            
Research and development obligation 1,321,278       1,321,278     1,321,278                
Accounts receivable 916,574       916,574     916,574     237,027          
Milestone payment     $ 250,000                          
Revenue recognized amount               0                
Alphazyme [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Proceeds from sale maturity and collections of investments             $ 60,977       1,300,000          
Alphazyme [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Ownership percentage                               1.99%
Research and Development [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue         350,046 $ 532,500   746,595 $ 1,253,013              
Gates Foundation [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Accounts receivable, after allowance for credit loss                             $ 3,092,136  
Proceeds 2,400,000                              
Total revenue         527,363     1,065,470                
Cost of revenue         447,140     969,989                
Gates Foundation [Member] | Forecast [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Proceeds                   $ 700,000            
CEPI [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue         287,209     462,754                
Cost of revenue         292,110     435,573                
Grant receivable                           $ 2,400,000    
Accounts receivable $ 462,754       $ 462,754     $ 462,754                
CEPI [Member] | Fondazione Biotecnopolo Di Siena Fbs [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Grant receivable                           $ 4,500,000    
Proliant Agreement [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
License and development initial term   10 years                            
License and development extension term   3 years                            
Initial up front payment                         $ 500,000      
Second payment upon completion transfer                         $ 500,000      
Proliant Agreement [Member] | Subsequent Event [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Final payment upon meeting certain productivity threshold                       $ 500,000        
Inzymes Agreement Aps [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Non refundable upfront payment received       $ 600,000                        
Deferred license revenue                     890,169          
Inzymes Agreement Aps [Member] | Research and Development [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue                     $ 25,000